UNC Health recently partnered with Gozio Health and WELL Health to add new features to its app. Patients can now download the app via a link sent in appointment reminder texts, view a map of immediate care options near them and access appointment wayfinding via their mobile phone calendar.
Entities like UNC Health Alliance are utilizing the Dallas, Texas company's cloud-based platform, which seeks to manage all the provider information across a healthcare organization.
Healthcare dignity for sale.
Early stage life science companies looking to fill a funding gap now have another avenue: a hospital. Rex Healthcare is creating a $10 million fund to invest in healthcare innovations and technologies. This new fund, called Rex Health Ventures, puts the Raleigh, North Carolina hospital among the few hospitals that have created venture capital fund. […]
How did our nation's most ambitious experiment in universal healthcare -- comprehensive Medicare coverage for every kidney failure patient -- descend from a "supremely hopeful moment" nearly four decades ago to a $20-billion-a-year "hulking monster" that kills thousands of patients? ProPublica asks in its latest investigative series.
Late Friday, the UNC Health Care System finalized a deal to affiliate with Wake Heart & Vascular Associates, a huge cardiology practice in Wake County long associated with WakeMed. It's part of UNC's bigger push to expand its heart business, according to the News & Observer.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Orlistat (sold as Xenical in prescription form and as Alli over the counter) is the only prescription weight-loss drug approved for long-term use now that Abbott removed Meridia from U.S. (where 68 percent of the population is overweight or obese) and Canadian markets, at the FDA's request, according to the Wall Street Journal's Health blog.
